Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Behrens

Showing results (31-40 of 119) with videos related to

Pageof 12
Sort By:
Rheumatology (Oxford, England)|July 17, 2018
Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumabFrank Behrens, Michaela Koehm, Eva C Schwaneck, et al.
BMC Rheumatology|December 24, 2019
Use of a "critical difference" statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritisFrank Behrens, Michaela Koehm, Eva C Schwaneck, et al.
Rheumatology (Oxford, England)|July 8, 2022
Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1Lars Erik Kristensen, Ahmed M Soliman, Kim Papp, et al.
BMC Medical Genetics|May 14, 2020
Genetic variants in FBLIM1 gene do not contribute to SAPHO syndrome and chronic recurrent multifocal osteomyelitis in typical patient groupsGunter Assmann, Michaela Köhm, Volker Schuster, et al.
Clinical Rheumatology|June 1, 2020
Correction to: Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort studyFrank Behrens, Hans-Peter Tony, Michaela Koehm, et al.
Arthritis Care & Research|March 19, 2016
Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid ArthritisEva C Scharbatke, Frank Behrens, Marc Schmalzing, et al.
Clinical Rheumatology|March 25, 2020
Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort studyFrank Behrens, Hans-Peter Tony, Michaela Koehm, et al.
Rheumatology and Therapy|September 6, 2022
Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN StudyJörg Wendler, Nils Damann, Marit Röcken, et al.
Rheumatology (Oxford, England)|August 24, 2016
Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritisErnest Choy, Daniel Aletaha, Frank Behrens, et al.
Clinical and Experimental Rheumatology|April 22, 2015
The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritisMartin Feuchtenberger, Stefan Kleinert, Eva-Christina Scharbatke, et al.
Pageof 12

Showing results (31-40 of 119) with videos related to

Sort By:
Pageof 12
Rheumatology (Oxford, England)|July 17, 2018
Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumabFrank Behrens, Michaela Koehm, Eva C Schwaneck, et al.
BMC Rheumatology|December 24, 2019
Use of a "critical difference" statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritisFrank Behrens, Michaela Koehm, Eva C Schwaneck, et al.
Rheumatology (Oxford, England)|July 8, 2022
Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1Lars Erik Kristensen, Ahmed M Soliman, Kim Papp, et al.
BMC Medical Genetics|May 14, 2020
Genetic variants in FBLIM1 gene do not contribute to SAPHO syndrome and chronic recurrent multifocal osteomyelitis in typical patient groupsGunter Assmann, Michaela Köhm, Volker Schuster, et al.
Clinical Rheumatology|June 1, 2020
Correction to: Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort studyFrank Behrens, Hans-Peter Tony, Michaela Koehm, et al.
Arthritis Care & Research|March 19, 2016
Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid ArthritisEva C Scharbatke, Frank Behrens, Marc Schmalzing, et al.
Clinical Rheumatology|March 25, 2020
Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort studyFrank Behrens, Hans-Peter Tony, Michaela Koehm, et al.
Rheumatology and Therapy|September 6, 2022
Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN StudyJörg Wendler, Nils Damann, Marit Röcken, et al.
Rheumatology (Oxford, England)|August 24, 2016
Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritisErnest Choy, Daniel Aletaha, Frank Behrens, et al.
Clinical and Experimental Rheumatology|April 22, 2015
The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritisMartin Feuchtenberger, Stefan Kleinert, Eva-Christina Scharbatke, et al.
Pageof 12